BioScrip, Inc. Press Release
ELMSFORD, N.Y.--(BUSINESS WIRE)--Jan. 25, 2008--BioScrip, Inc. (Nasdaq: BIOS), a comprehensive pharmaceutical care solutions company, today announced that on January 24, 2008, it received written notification from the Nasdaq Listing Qualifications Department ("Nasdaq") that it had violated the shareholder approval requirement set forth in Nasdaq Marketplace Rule 4350(i); the notice also indicated that the Nasdaq staff had determined that the Company has regained compliance with the Rule and, with the issuance of this press release the matter is now closed. The Company violated the above-reference Rule by delivering to its non-employee directors in May 2007 option agreements for an aggregate of 55,000 shares of Company common stock under a director stock option plan that had expired prior to that date. The Company had previously notified Nasdaq that the option agreements had been erroneously issued, that the options purportedly evidenced by the option agreements were never granted and that, upon discovery of the error, the Company had cancelled the option agreements.
About BioScrip, Inc.
BioScrip, Inc. (www.bioscrip.com) (Nasdaq: BIOS) is a specialty pharmaceutical health care organization that partners with patients, physicians, health care payors and pharmaceutical manufacturers to provide access to medications and management solutions to optimize outcomes for chronic and other complex health care conditions.
Forward Looking Statements
This press release may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward looking statements as a result of various factors. Important factors that could cause such differences are described in the Company's periodic filings with the Securities and Exchange Commission.
CONTACT:
BioScrip, Inc.
Stanley G. Rosenbaum, 952-979-3768
Executive Vice President and
Chief Financial Officer
srosenbaum@bioscrip.com
SOURCE:
BioScrip, Inc.